Members of the Khondrion team will be attending Mitochondrial Medicine 2019 on 11-13 December 2019. The event will bring together leaders in the field of translational mitochondrial medicine, with a programme designed to engage and inspire the next generation of mitochondrial researchers. Read more about the event.
Find more articles
- UMDF and Khondrion Announce The Mito Fund’s Investment in Khondrion to Support Development of One of the Most Advanced Drug Candidates for Primary Mitochondrial Disease
- Khondrion receives FDA clearance of IND application for pivotal Phase 3 clinical trial of sonlicromanol for the treatment of primary mitochondrial disease
- Khondrion and Amsterdam UMC announce to initiate Phase 2 Clinical Trial of Sonlicromanol to Combat Long-Term Post-COVID Symptoms
- Khondrion announces publication in Brain of integrated Phase 2b program demonstrating disease-modifying potential of sonlicromanol in primary mitochondrial disease
- Khondrion to Present Promising Advances in Mitochondrial Disease Therapy at Bio-Europe and Investival Showcase Events
- Khondrion to present at Mitocon’s 14th Mitochondrial Disease Conference
- Khondrion appoints Jasper Levink as Chief Financial and Business Officer
- EuroHealth Leaders Magazine interviewed Khondrion’s CEO Jan Smeitink
- Khondrion announces grant of patents in the US and Europe for its lead candidate sonlicromanol, covering the anti-inflammatory effect on mPGES-1
- Khondrion to participate in the 16th Annual Dutch Inborn Error Meeting and the United Mitochondrial Disease Foundation (UMDF) Bench to Bedside seminar
- Khondrion joins the NADIS International Student Training Network
- 2022 – A Year in Review
- Khondrion announces sonlicromanol Phase IIb progress supporting Phase III development in MELAS spectrum disorders
- Patient Perspective: A conversation with Kate Murray – CEO and President, MitoCanada
- Khondrion to participate in World Mitochondria Society’s Targeting Mitochondria 2022 Congress
- Patient Perspective: A conversation with Sean Murray – CEO, The Mito Foundation
- Interview with Tom Pulles, Chief Medical Officer at Khondrion
- Khondrion to participate in mitoNice international congress dedicated to mitochondrial medicine
- Patient Perspective: A conversation with Kasey Woleben – Co-founder, and Sophia Zilber – Board Member, Patient Registry Director, Cure Mito Foundation
- Khondrion appoints Tom Pulles, MD, as Chief Medical Officer
- Patient Perspective: A conversation with Philip Yeske, PhD – Science & Alliance Officer, UMDF
- Patient Perspective: A conversation with Alison Maguire – Head of Research & Finance, The Lily Foundation
- Patient Perspective: A conversation with Kira Mann – Newly appointed IMP Chair
- Khondrion completes enrollment in KHENERGYZE Phase IIb trial evaluating sonlicromanol in adult patients with MELAS spectrum disorders
- 2021 – A Year in Review